Ayala Pharmaceuticals, Inc. (ADXS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ayala Pharmaceuticals, Inc. (ADXS) trades at $0.60 with AI Score 43/100 (Grade C). Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing small molecule therapeutics for rare tumors and aggressive cancers. Market cap: $25.71M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for ADXS: ADXS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ADXS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ADXS: the 1 perspectives are evenly split.
How is this calculated? →Ayala Pharmaceuticals, Inc. (ADXS) Healthcare & Pipeline Overview
Ayala Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in small molecule therapeutics for rare and aggressive cancers. Their pipeline focuses on AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236) for acute myeloid leukemia, positioning them in a niche market within the broader oncology landscape.
What Is the Investment Thesis for ADXS?
Ayala Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is significantly influenced by the clinical progress of its lead drug candidates, AL102 and aspacytarabine (BST-236). Successful clinical trials and regulatory approvals could drive substantial value appreciation. However, potential investors should be aware of the inherent risks associated with clinical-stage pharmaceutical companies, including clinical trial failures, regulatory setbacks, and the need for additional capital. The company's negative profit margin of -369784.6% underscores the importance of pipeline advancement for future revenue generation. The beta of -4.03 suggests an inverse correlation with the market, but this should be interpreted cautiously given the company's specific circumstances. Key catalysts include upcoming clinical trial data releases and potential partnerships or licensing agreements.
Based on FMP financials and quantitative analysis
ADXS Key Highlights
- Market capitalization of $25.71M reflects the company's early stage and speculative nature.
- Negative P/E ratio of -0.08 indicates that the company is currently unprofitable, common for clinical-stage biotech firms.
- Profit margin of -369784.6% highlights the significant research and development expenses relative to revenue.
- Beta of -4.03 suggests a negative correlation with the market, potentially offering some diversification benefit, but should be interpreted cautiously.
- No dividend yield reflects the company's focus on reinvesting capital into research and development.
Who Are ADXS's Competitors?
ADXS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $63.42 | -3.07% | $2.73B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $21.82 | +4.45% | $1.93B | 79 |
| CGEN Compugen Ltd. | $2.28 | +7.04% | $215.58M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.13 | +1.10% | $389.54M | 76 |
| AXSM Axsome Therapeutics, Inc. | $244.31 | +1.52% | $12.57B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $125.59 | +4.26% | $6.30B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.21 | +0.79% | $1.58B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ADXS's Key Strengths?
- Focus on rare tumors and aggressive cancers with high unmet need.
- Proprietary small molecule therapeutics.
- Clinical-stage pipeline with potential for significant value creation.
- Experienced management team with expertise in drug development.
What Are ADXS's Weaknesses?
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Small team size.
- Negative profit margin.
What Could Drive ADXS Stock Higher?
- Clinical trial data releases for AL102 in desmoid tumors.
- Clinical trial data releases for aspacytarabine (BST-236) in AML.
- Potential partnerships or licensing agreements with larger pharmaceutical companies.
- Regulatory interactions with the FDA and EMA.
- Advancement of preclinical programs.
What Are the Key Risks for ADXS?
- Financial-distress signal — its Altman Z-Score of -24.78 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for AL102 or aspacytarabine (BST-236).
- Regulatory setbacks or delays in approval process.
- Competition from other companies developing therapies for similar indications.
- Need for additional capital to fund research and development.
- Dependence on key personnel.
What Are the Growth Opportunities for ADXS?
- Expansion into new therapeutic areas: Ayala Pharmaceuticals, Inc. has the opportunity to leverage its expertise in small molecule therapeutics to expand its pipeline into new therapeutic areas beyond desmoid tumors and AML. This could involve targeting other rare cancers or exploring indications in related fields such as hematology or immunology. The market for targeted cancer therapies is projected to reach $174 billion by 2027, providing a significant growth opportunity for companies with innovative technologies.
- Strategic partnerships and collaborations: Ayala Pharmaceuticals, Inc. can accelerate its drug development efforts and expand its market reach through strategic partnerships and collaborations with larger pharmaceutical companies or research institutions. These partnerships can provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation and share the risks associated with drug development.
- Advancement of AL102 for desmoid tumors: The successful development and commercialization of AL102 for desmoid tumors represents a significant growth opportunity for Ayala Pharmaceuticals, Inc. Desmoid tumors are rare and debilitating, with limited treatment options currently available. AL102 has the potential to become a first-line therapy for this indication, generating substantial revenue for the company. The desmoid tumor market is estimated to reach $300 million by 2028.
- Development of aspacytarabine (BST-236) for AML: The development of aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML) represents another key growth driver for Ayala Pharmaceuticals, Inc. AML is a aggressive blood cancer with high unmet medical need. BST-236 has the potential to improve outcomes for patients with AML, particularly those who are unfit for standard chemotherapy regimens. The AML market is projected to reach $3.8 billion by 2027.
- Geographic expansion: Ayala Pharmaceuticals, Inc. has the opportunity to expand its geographic presence beyond the United States and Europe. Emerging markets such as China and India are experiencing rapid growth in healthcare spending and increasing demand for innovative cancer therapies. By establishing a presence in these markets, Ayala can tap into a large and growing patient population.
What Opportunities Does ADXS Have?
- Strategic partnerships and collaborations.
- Expansion into new therapeutic areas.
- Accelerated regulatory pathways for rare diseases.
- Growing demand for targeted cancer therapies.
What Threats Does ADXS Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from larger pharmaceutical companies.
- Patent expirations.
What Are ADXS's Competitive Advantages?
- Proprietary small molecule therapeutics targeting specific cancer pathways.
- Patent protection for its drug candidates.
- Focus on rare tumors and aggressive cancers with limited treatment options.
- Clinical data demonstrating efficacy and safety of its therapies.
What Does ADXS Do?
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company dedicated to developing and commercializing targeted therapies for patients with rare tumors and aggressive cancers. The company's primary focus is on addressing unmet medical needs in areas where current treatment options are limited or ineffective. Ayala's lead drug candidates include AL102, an oral gamma secretase inhibitor being developed for the treatment of desmoid tumors, and aspacytarabine (BST-236), a novel anti-metabolite in development for the treatment of acute myeloid leukemia (AML). The company's approach involves identifying and developing small molecule therapeutics that can selectively target key pathways involved in cancer growth and progression. Ayala's pipeline reflects a commitment to precision medicine, aiming to deliver personalized treatment options that can improve outcomes for patients with specific genetic or molecular profiles. The company is based in Wilmington, Delaware, and operates with a team of approximately 20 employees, reflecting a lean and focused organizational structure.
What Products and Services Does ADXS Offer?
- Develops small molecule therapeutics for rare tumors and aggressive cancers.
- Focuses on targeted therapies for unmet medical needs in oncology.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Aims to commercialize its therapies to improve patient outcomes.
- Researches and identifies novel drug targets and pathways in cancer.
- Utilizes precision medicine approaches to personalize treatment.
How Does ADXS Make Money?
- Develops and patents novel small molecule therapeutics.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments, royalties, and potential direct sales.
- Focuses on niche markets with high unmet medical needs.
What Industry Does ADXS Operate In?
Ayala Pharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The oncology market, in particular, is a major area of focus, driven by the increasing prevalence of cancer and the demand for more effective and targeted therapies. Ayala's focus on rare tumors and aggressive cancers positions it in a niche segment of the market, potentially reducing competition from larger pharmaceutical companies. However, the company faces competition from other biotechnology firms and research institutions developing therapies for similar indications. The biotechnology industry is subject to rapid innovation and evolving regulatory landscapes, requiring companies to adapt quickly to remain competitive.
Who Are ADXS's Key Customers?
- Patients with rare tumors and aggressive cancers.
- Oncologists and hematologists who treat these patients.
- Hospitals and cancer centers.
- Pharmaceutical companies through licensing agreements.
Company Profile
Ayala Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Monmouth Junction, US. The company is led by CEO Kenneth A. Berlin. ADXS has traded publicly since 2020.
Ayala Pharmaceuticals, Inc. (ADXS) Valuation Context
Valued at $25.71M, ADXS is classified as a micro-cap stock. Relative to its peer group, ADXS's quantitative score of 43/100 is below the peer average of 76/100.
F-Score 1/9Financial Health
Ayala Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.78 places it in the distress zone, a signal of elevated financial risk.
ADXS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Ayala's upcoming clinical trials, indicating potential positive outcomes.
- Community sentiment has shifted positively as discussions around their innovative therapies gain traction on social platforms.
- Analysts are increasingly optimistic about the company's pipeline, with new treatments showing promise in early-stage studies.
- Increased media coverage highlighting Ayala's unique approach to cancer treatment has sparked interest among retail investors.
Bear Case
- Concerns linger over the company's cash runway, with some investors questioning sustainability without immediate revenue generation.
- Recent social sentiment shows skepticism, particularly regarding the timeline for clinical trial results and regulatory approvals.
- Market perception remains cautious as past performance has led to doubts about the efficacy of their treatments.
- Insider selling activity has raised red flags for some, suggesting that key stakeholders may not be fully confident in the company's direction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ADXS Latest News
-
List of Companies Reaching Yearly Lows Tuesday
· Jul 23, 2019
ADXS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADXS.
Price Targets
Wall Street price target analysis for ADXS.
ADXS MoonshotScore
What does this score mean?
The MoonshotScore rates ADXS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kenneth A. Berlin
CEO
Kenneth A. Berlin serves as the CEO of Ayala Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held leadership positions at various companies, overseeing drug development, commercialization, and strategic planning. Berlin's expertise spans across multiple therapeutic areas, including oncology. His educational background includes advanced degrees in business and science.
Track Record: Under Kenneth A. Berlin's leadership, Ayala Pharmaceuticals, Inc. has focused on advancing its clinical pipeline, particularly AL102 and aspacytarabine (BST-236). He has overseen the initiation and execution of clinical trials, as well as the development of strategic partnerships. Key milestones include securing funding for research and development and achieving regulatory designations for its drug candidates.
ADXS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ayala Pharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies on the OTC Other tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements.
- Research the background of the management team.
- Assess the company's business model and competitive landscape.
- Review the company's SEC filings (if any).
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Confirm the company's good standing with regulatory agencies.
- Experienced management team.
- Focus on developing innovative cancer therapies.
- Clinical trial progress.
- Patent protection for its drug candidates.
- Scientific advisory board.
Common Questions About ADXS (Healthcare)
What does Ayala Pharmaceuticals, Inc. do?
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for rare tumors and aggressive cancers. Their lead candidates include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), a novel anti-metabolite for first-line treatment in unfit acute myeloid leukemia. The company aims to address unmet medical needs in areas where current treatment options are limited or ineffective, utilizing a precision medicine approach to deliver personalized treatment options.
What are the main risks for ADXS?
The main risks for Ayala Pharmaceuticals, Inc. include the potential for clinical trial failures, regulatory setbacks, and competition from other companies developing therapies for similar indications. The company also faces the risk of needing additional capital to fund research and development, as well as dependence on key personnel. Given that the company trades on the OTC Other tier, there are additional risks associated with limited financial disclosure, low trading volume, and potential price manipulation.
What are the key growth opportunities for ADXS in healthcare?
Ayala Pharmaceuticals, Inc. has several key growth opportunities within the healthcare sector. These include expanding into new therapeutic areas beyond desmoid tumors and AML, forming strategic partnerships and collaborations with larger pharmaceutical companies, and advancing AL102 for desmoid tumors and aspacytarabine (BST-236) for AML. Geographic expansion into emerging markets also presents a significant opportunity. Success in these areas could drive substantial revenue growth and increase shareholder value.
How does Ayala Pharmaceuticals, Inc. manage patent expiration risks?
As a clinical-stage company, Ayala Pharmaceuticals, Inc.'s primary focus is currently on developing and patenting its lead drug candidates, AL102 and aspacytarabine (BST-236). The company seeks to secure strong patent protection for its innovative therapies to maintain market exclusivity and prevent generic competition. While patent expiration is a long-term concern, Ayala's immediate priority is to advance its pipeline through clinical trials and regulatory approvals, which will ultimately determine the long-term value of its intellectual property.
What are the key factors to evaluate for ADXS?
Ayala Pharmaceuticals, Inc. (ADXS) holds an AI score of 43/100 (low). Not financial advice.
How frequently does ADXS data refresh on this page?
ADXS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ADXS's recent stock price performance?
Ayala Pharmaceuticals, Inc. (ADXS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare tumors and aggressive cancers with high unmet need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADXS overvalued or undervalued right now?
Valuing Ayala Pharmaceuticals, Inc. (ADXS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data can be less reliable than major exchanges.
- AI analysis pending for ADXS.